Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ardelyx (ARDX)
NASDAQ:ARDX
Ardelyx (ARDX) Stock Price & Analysis
1,403 Followers
ARDX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.16 - $10.13
Previous Close$7.57
Volume16.88M
Average Volume (3M)4.97M
Market Cap
$1.21B
Enterprise Value$1.67B
Total Cash (Recent Filing)$202.58M
Total Debt (Recent Filing)$104.93M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Aug 09, 2024EPS Estimate
-$0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding233,976,572
10 Day Avg. Volume4,010,326
30 Day Avg. Volume4,969,355
Standard Deviation0.24
R-Squared0.03
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)9.55
Price to Sales (P/S)41.94
Price to Cash Flow (P/CF)-10.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue10.52
Enterprise Value/Gross Profit15.69
Enterprise Value/Ebitda-35.72
Forecast
1Y Price Target
$12.75Price Target Upside147.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Ardelyx News
PremiumCompany Announcements
Ardelyx Shareholders Approve Key Corporate Governance Updates
Bulls Say, Bears Say
Bulls Say
Market UptakeThe ongoing US commercial launch of Ibsrela in IBS-C has been robust, indicating a strong market uptake.
Product Launch SuccessThe Xphozah launch is off to a strong start with 1Q24 revenues of $15M, more than double the estimate and significantly above consensus.
Revenue GrowthArdelyx reported 1Q24 total revenues of $46M, showing a 34% increase quarter-over-quarter, and exceeding both FactSet consensus and internal estimates by ~15% and 24%, respectively.
Bears Say
Legislative UncertaintyThe timing of the exit is not ideal given the uncertainty surrounding potential passage of the KIDNEY Patient act legislation.
Management ChangesChief Commercial Officer Susan Rodriguez will resign from her current position.
Product Launch ChallengesThe main pushback on the XPHOZAH launch will be how Ardelyx manages the seemingly increasing likelihood that the oral dialysis drugs will enter the bundle sooner vs later.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
ARDX FAQ
What was Ardelyx’s price range in the past 12 months?
Ardelyx lowest stock price was $3.16 and its highest was $10.13 in the past 12 months.
What is Ardelyx’s market cap?
Currently, no data Available
When is Ardelyx’s upcoming earnings report date?
Ardelyx’s upcoming earnings report date is Aug 09, 2024 which is in 37 days.
How were Ardelyx’s earnings last quarter?
Ardelyx released its earnings results on May 02, 2024. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.147 by $0.037.
Is Ardelyx overvalued?
According to Wall Street analysts Ardelyx’s price is currently Undervalued.
Does Ardelyx pay dividends?
Ardelyx does not currently pay dividends.
What is Ardelyx’s EPS estimate?
Ardelyx’s EPS estimate is -$0.11.
How many shares outstanding does Ardelyx have?
Ardelyx has 233,976,580 shares outstanding.
What happened to Ardelyx’s price movement after its last earnings report?
Ardelyx reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.147. Following the earnings report the stock price went up 28.424%.
Which hedge fund is a major shareholder of Ardelyx?
Among the largest hedge funds holding Ardelyx’s share is Oracle Investment Management Inc. It holds Ardelyx’s shares valued at 15M.
---
Ardelyx Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.75 (147.33% Upside)
$12.75 (147.33% Upside)
Blogger Sentiment
Bullish
ARDX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
123.30%
12-Months-Change
Fundamentals
Return on Equity
-47.64%
Trailing 12-Months
Asset Growth
57.77%
Trailing 12-Months
Company Description
Ardelyx
Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of renal diseases. It focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.
---
ARDX Earnings Call
Q1 2024
0:00 / 0:00
---
ARDX Stock 12 Month Forecast
Average Price Target
$12.75
▲(147.33% Upside)
Technical Analysis
Best Analysts Covering ARDX
1 Year
1 Year Success Rate
11/18 ratings generated profit
1 Year Average Return
+49.31%
reiterated a buy rating last month
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 61.11% of your transactions generating a profit, with an average return of +49.31% per trade.
---